Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

• Main Authors: Adelaide A. Hebert (Author), Carsten Flohr (Author), H. Chih-ho Hong (Author), Alan D. Irvine (Author), Evangeline Pierce (Author), Hany Elmaraghy (Author), Sreekumar Pillai (Author), Zach Dawson (Author), Sherry Chen (Author), Clara Armengol (Author), Elaine Siegfried (Author), Stephan Weidinger (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

AbstractBackground Lebrikizumab, a high-affinity monoclonal antibody targeting IL-13, previously demonstrated clinical efficacy in three randomized, double-blind, placebo-controlled Phase 3 trials that included adults and adolescents with moderate-to-severe atopic dermatitis (AD): ADvocate1, ADvocat...